An initial company experience gained from using preclinical CiPA testing paradigm in a drug discovery setting: Challenges still lying ahead

Delaunois Annie; Rjasanow Alexandra; Hebeisen Simon; Passini Elisa; Rodriguez Blanca; Smith Godfrey; Bryant Mark; Valentin Jean-Pierre

首页> 外文期刊>Journal of Pharmacological and Toxicological Methods >An initial company experience gained from using preclinical CiPA testing paradigm in a drug discovery setting: Challenges still lying ahead

【24h】

An initial company experience gained from using preclinical CiPA testing paradigm in a drug discovery setting: Challenges still lying ahead

机译：在药物发现环境中使用临床前CIPA检测范式获得了初始公司体验：挑战仍在前方

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of Pharmacological and Toxicological Methods》 |2019年第2019期|共5页
作者
Delaunois Annie; Rjasanow Alexandra; Hebeisen Simon; Passini Elisa; Rodriguez Blanca; Smith Godfrey; Bryant Mark; Valentin Jean-Pierre;
展开▼
作者单位

UCB Biopharma Braine Lalleud Belgium;

BSYS GmbH Witterswil Switzerland;

BSYS GmbH Witterswil Switzerland;

Univ Oxford Dept Comp Sci Oxford England;

Univ Oxford Dept Comp Sci Oxford England;

Clyde Biosci Ltd Newhouse Scotland;

Clyde Biosci Ltd Newhouse Scotland;

UCB Biopharma Braine Lalleud Belgium;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. An initial company experience gained from using preclinical CiPA testing paradigm in a drug discovery setting: Challenges still lying ahead [J] . Delaunois Annie, Rjasanow Alexandra, Hebeisen Simon, Journal of Pharmacological and Toxicological Methods . 2019,第期

机译：在药物发现环境中使用临床前CIPA检测范式获得了初始公司体验：挑战仍在前方
2. Connecting Patients With Specialty Products Part 2: The future of specialty drug distribution Previously, this series described distribution channels through which specialty drugs move to patients. This installment discusses changes and challenges that lie ahead, especially at the dispensing end. [J] . JACK MCCAIN Biotechnology healthcare . 2012,第3期

机译：将患者与特色产品联系起来第2部分：特色药物分销的未来以前，本系列文章介绍了特色药物向患者转移的分销渠道。本期文章讨论了即将发生的变化和挑战，特别是在分配端。
3. The New Pre-Preclinical Paradigm: Compound Optimization in Early and Late Phase Drug Discovery [J] . Gary W. Caldwell David M. Ritchie John A. Masucci William Hageman Zhengyin Yan Current Topics in Medicinal Chemistry . 2001,第5期

机译：新的临床前范例：早期和晚期药物发现中的化合物优化
4. The 12-step approach to recovery from alcohol and drug dependence: Test of a mediation model using a loss-gain paradigm [D] . Streifel, Cathy M. 2009

机译：从酒精和药物依赖中恢复的12个步骤：使用损失获得范式的中介模型测试
5. Discovery and Development of Antiviral Drugs for Biodefense: Experience of a Small Biotechnology Company [O] . Tove C. Bolken, Dennis E. Hruby -1

机译：用于生物防御的抗病毒药物的发现和开发：一家小型生物技术公司的经验
6. The fourth scientific discovery paradigm for precision medicine and healthcare: Challenges ahead [O] . Li Shen, Jinwei Bai, Jiao Wang, 2021

机译：第四次科学发现范式为精密医学和医疗保健：未来挑战

An initial company experience gained from using preclinical CiPA testing paradigm in a drug discovery setting: Challenges still lying ahead

著录项

相似文献

相关主题

期刊订阅